ArticleBMC cancer2025

A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.

Liping Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.